| Thermo Fisher–Univ Basel: DNA sequencing, 201704– collab Univ Hospital joins NGS Companion Dx Center of Excellence Program |
2017-04-18 |
| Bayer–Ten Bridge Communications: public relations, 201704 service existent CRISR Tx/Bayer jv Casebia by Ten Bridge |
2017-04-17 |
| CRISPR Therapeutics–StrideBio: AAV vectors, 201704– collab developm + license option usingStrideBio’s vectors for in vivo CRISPR/Cas9-based therapies |
2017-04-17 |
| MOCON–AMETEK: investment, 201704– acquisition of MOCON Inc for aggregate enterprise value of $182m |
2017-04-17 |
| Polyphor–SEVERAL: investment, 201704 private financing round CHF40m with CHF10m upfront + CHF30m at positive ph2 study end in 2017H2 |
2017-04-12 |
| Adhesys Medical–Grünenthal: investment, 201704 acquisition of Adhesys by Grünenthal |
2017-04-07 |
| Adhesys Medical–GSK Stockmann: legal services, 201704 supply legal advisor for sale of Adhesys Medical to Grünenthal |
2017-04-07 |
| Biotest–Ashurst: legal services, 201704 supply service legal advisor with regard to sale of Biotest AG to Ceat Group (CN) |
2017-04-07 |
| Asceneuron–Instinctif Partners: public relations, 201704 service existent by Instinctif Partners |
2017-04-06 |
| Berlin Institute of Health–Labfolder: electronic lab notebook, 201704– supply license Labfolder s/w to BIH (Charité + MDC) |
2017-04-06 |
| Labfolder–MC Services: public relations, 201704 service existent by MC Services AG |
2017-04-06 |
| Novartis–Lubris: rh lubricin, 201704– license €na exercise of option for ECF843 for ophthalmic indications ww excl Europe |
2017-04-06 |
| Biosyntia–FGen: biological vitamin production, 201704– collob developm of microbial strains for production of specific B vitamins |
2017-04-05 |
| MTIP MedTech Innovation Partners–SEVERAL: investment, 201704 final closing w addit CHF30m bringing total fund size of 1st MTIP Fund to CHF60m |
2017-04-04 |
| Topas Therapeutics–MC Services: public relations, 201704 service existent by MC Services AG |
2017-04-04 |
| MKS Instruments–Sartorius: investment, 201704 acquisition $72.5m of MKS Instruments AB (Umetrics) by Sartorius Stedim Biotech |
2017-04-03 |
| Bentekk–Dräger: investment, 201704 acquisition of majority stake by Dräger |
2017-04-01 |
| Yumda–Chemie.DE: investment, 201704 acquisition of Yumda GmbH by Chemie.DE Information Service GmbH |
2017-04-01 |
| Eisai–Calypso Biotech: therapeutic antibody, 201703– ww license + collab for MMP-9 MAb CALY-001 with EA Pharma Co Ltd |
2017-03-31 |
| Innovative Medicines Initiative–Qiagen: cancer biomarker, 201703– collab Qiagen joins CANCER-ID project |
2017-03-30 |
| Novartis–Oxford BioMedica: lentiviral vector technology, 201703 supply existent OBM sole producer of lentiviral vector expressing CTL019 |
2017-03-30 |
| Symetis–Boston Scientific: investment, 201703– acquisition $435m in cash ANNOUNCED |
2017-03-30 |
| Biotest–Creat (CN): investment, 201703–201801 public cash tender offer €1.3b incl net debt for all shares w €28.5/ordinary + €19m/preference share |
2017-03-29 |
| Versantis–SEVERAL: investment, 201703 financing round Series A CHF4.4m led by Redalpine Venture Partners |
2017-03-29 |
| Bayer–Icagen: drug discovery assays, 201703– collab developm of XRpro Assays for early discovery programs in area of transporter targets |
2017-03-28 |
| Menarini–Selvita: kinase inhibitor, 201703– license ww to dual PIM/FLT3 kinase inhibitor SEL24 to Berlin-Chemie |
2017-03-28 |
| Ono Pharmaceutical–Numab: antibody cancer drug, 201703– research + option agreem up to CHF258m + royalties for multi-specific antibody |
2017-03-28 |
| Institut Pasteur–Bruker: NMR spectrometer, 201703 supply existent early customer for AVANCE NEO 800 MHz system |
2017-03-27 |
| PureTech Health–Novartis: investment, 201703 equity position in new resTORbio subsidary for Novartis as part of mTORC1 inhibitor license deal |
2017-03-24 |
| PureTech Health–Novartis: mTORC1 inhibitors, 201703– license excl to 2 clin stage programs to be developed by new resTORbio subsidary |
2017-03-24 |
| Numares–Univ Oxford: NMR-based IVD tests, 201703– collab developm of multiple sclerosis test using Axinon IVD system + MGS technology |
2017-03-23 |
| BASF–MIT: CRISPR technology, 201703– license ww for agricultural + industrial microbiology applications from Broad Institute |
2017-03-22 |
| Symetis–SEVERAL: investment, 201703 IPO at Euronext NOT REALISED because of acquistion offer by Boston Scientific |
2017-03-17 |
| Medac–Cevec: rec protein production technology, 201703– license to CAP GT technology for oncology products |
2017-03-16 |
| Provecs–Cevec: rec protein production technology, 201703– license non-excl extension to CAP GT technology for cancer immunotherapy |
2017-03-16 |
| CRISPR Therapeutics–MaxCyte: gene transfer technology, 201703– license non-excl to CRISPR Tx + Caseio for using Flow Electroporation technology |
2017-03-14 |
| NeoGenomics–AstraZeneca: cancer research tests, 201703– collab using automated Definiens biomarker solutions for IHC services of NeoGenomics |
2017-03-13 |
| ILC Micro-Chem–SGS: investment, 201703 acquisition of ILC by SGS |
2017-03-09 |
| Breath Therapeutics–Gimv: investment, 201703 financing round Series A totalling €43.5m incl co-led by Gimv + Sofinnova Partners |
2017-03-08 |
| Breath Therapeutics–MC Services: public relations, 201703 service existent by MC Services AG |
2017-03-08 |
| Breath Therapeutics–SEVERAL: investment, 201703 financing round Series A €43.5m co-led by Gimv + Sofinnova Partners |
2017-03-08 |
| Breath Therapeutics–Sofinnova: investment, 201703 financing round Series A totalling €43.5m incl co-led by Gimv + Sofinnova Partners |
2017-03-08 |
| Fresenius–Wacker: rec protein production, 201703 collab use of Wacker Biotech’s FOLDTEC technology to produce Fabs for Fresenius |
2017-03-08 |
| Illumina–Endress+Hauser: automated liquid handling, 201703– collab developm + marketing of AJ CyBio FeliX system with Infinium XT BeadChip |
2017-03-08 |
| InGeneron–Sanford Health: investment, 201703– tranched investment Series D $20m from Sanford Health |
2017-03-06 |
| Alcami–Bruker: X-ray technology, 201703 supply of D8 Discover HTS XRD system to Alcami site in Weert NL |
2017-03-03 |
| Essen BioScience–Sartorius: investment, 201703–201704 acquisition $320m in cash of Essen BioScience from SFW Capital Partners |
2017-03-03 |
| Neurovance–Novartis: investment, –201703 existent investment of NVF when acquisition of Neurovance by Otsuka announced |
2017-03-03 |
| Neurovance–Otsuka: investment, 201703– acquisition $100m upfront + $150m milestones of Neurovance by Otsuka America Inc |
2017-03-03 |
| CRISPR Therapeutics–W2O Group: public relations, 201703 service existent by W2O Group |
2017-03-02 |
| CRISPR Therapeutics–Westwicke Partners: public relations, 201703 service existent investor relations by Westwicke Partners |
2017-03-02 |
| Arsanis–Ten Bridge Communications: public relations, 201703 service existent by Ten Bridge |
2017-03-01 |
| Avillion–Merck (DE): Nanobody, 201703– collab ww clinical development + regulatory submission of M1095 anti IL-17 A/F Nanobody |
2017-03-01 |
| Axolabs–LGC: investment, 201703 acquisition of Axolabs GmbH by LGC |
2017-03-01 |
| InfanDx–Arnika Beteiligungen: investment, 201703 investment by new investor Arnika Beteiligungen GmbH |
2017-03-01 |
| Omeicos–SEVERAL: investment, 201703 1st closing €8.3m of financing round Series B led by Vesalius Biocapital II |
2017-03-01 |
| Addex–SEVERAL: investment, 201702 private placement CHF3m with 1.5m treasury shares at CHF2/share led by Herculis Partners SA |
2017-02-28 |
| Sanofi–Lonza: rec protein production, 201703– collab 50/50 jv to establish biologics production facility in CH w initial investment of CHF290 (€270m) |
2017-02-27 |
| Adaptimmune–Ally Bridge Group: investment, 201702 existent investment of ABG |
2017-02-23 |
| Galenica–Ally Bridge Group: investment, 201702 investment €na by ABG |
2017-02-23 |
| Nabriva–Ally Bridge Group: investment, 201702 investment €na by ABG |
2017-02-23 |
| Tesaro–Ally Bridge Group: investment, 201702 existent investment of ABG |
2017-02-23 |
| WuXi PharmaTech–Ally Bridge Group: investment, 201702 existent investment of ABG |
2017-02-23 |
| Neovacs–ActeaVentures: business consulting, 201702 supply service business development advisor for Neovacs license deal w BioSense Global LLC |
2017-02-21 |
| Bayer–Yara: digital farming, 201702– collab + license ww to ImageIT mobile imaging technology for plant monitoring + farming recommendations |
2017-02-20 |
| Oncgnostics–Thuringia (govt): investment, 201702 additional investment of €500k from bm|t |
2017-02-20 |
| BioMedPartners–SEVERAL: investment, 201702 first closing CHF75m of BioMedInvest III fund incl cornerstone investor EIF + Berner Kantonalbank |
2017-02-16 |
| Selecta Biosciences–Lonza: gene therapy products, 201702– supply contract manufacturing of Anc80-AAV-based gene therapy product by Lonza Houston Inc |
2017-02-16 |
| Boehringer–Cornell Univ: drug discovery, 201702– collab 3y identify COPD treatm approaches Weill Cornell Medicine Dept of Genetic Medicine |
2017-02-15 |
| Boehringer–Inventiva: pharmaceutical, 201702 collab r+d existent |
2017-02-15 |
| Jecure Therapeutics–Versant Ventures: investment, 201702 financing round Series A $20m from founding investor Versant Ventures |
2017-02-15 |
| Immunicum–MacDougall Biomedical Communications: public relations, 201702 service existent by MacDougall |
2017-02-13 |
| Santhera–SEVERAL: credit, 201702–202202 senior unsecured convertible bonds CHF60m 5% due 202202 |
2017-02-10 |
| Evotec–Novo Group: investment, 201702 strategic investment of €90.3m 13.15m new Evotec shares at €6.87/share resulting in 8.9% ownership by Novo A/S |
2017-02-09 |
| NewLink Genetics–Cevec: rec protein production technology, 201702– license €na to CAP GT + CAP Go cell lines for Zika vaccine developm + commerc |
2017-02-09 |
| Albany Molecular–Bruker: mass spectrometer, 201702 supply MALDI PharmaPulse system to AMRI by Bruker Daltonics + HighRes Biosolutions |
2017-02-07 |
| Atriva Therapeutics–High-Tech Gründerfonds: investment, 201702 seed financing round led by Stichting Participatie Atriva + HTGF |
2017-02-07 |
| Atriva Therapeutics–SEVERAL: investment, 201702 seed financing round led by Stichting Participatie Atriva + HTGF plus private investors |
2017-02-07 |
| Atriva Therapeutics–Stichting Participatie Atriva: investment, 201702 seed financing round led by SPA + HTGF |
2017-02-07 |
| Bruker–Albany Molecular: mass spectrometry, 201702– collab developm of HTS applications using MALDI PharmaPulse system from Bruker + HighRes |
2017-02-07 |
| Labor Limbach–Numares: NMR-based IVD tests, 201702 collab existent Labor Limbach offers IVD test LipoComplete |
2017-02-07 |
| Prexton Therapeutics–Forbion: investment, 201702 financing round Series B totalling €29m co-led by new investors Forbion + Seroba |
2017-02-07 |
| Prexton Therapeutics–Merck (DE): investment, 201702 financing round Series B totalling €29m incl returning co-investor Merck Ventures |
2017-02-07 |
| Prexton Therapeutics–Seroba: investment, 201702 financing round Series B totalling €29m co-led by new investors Forbion + Seroba |
2017-02-07 |
| Prexton Therapeutics–SEVERAL: investment, 201702 financing round Series B €29m co-led by new investors Forbion + Seroba |
2017-02-07 |
| Prexton Therapeutics–Sunstone Capital: investment, 201702 financing round Series B totalling €29m incl returning co-investor Sunstone Capital |
2017-02-07 |
| Prexton Therapeutics–Ysios Capital: investment, 201702 financing round Series B totalling €29m incl returning co-investor Ysios Capital |
2017-02-07 |
| GSK–Bruker: mass spectrometer, 201702 supply existent MALDI PharmaPulse 2.0 incl rapifleX MALDI-TOF System at GSK Platform Tech + Science group |
2017-02-06 |
| Wilex–Hopp Group: investment, 201702– financing commitment of up to €10m by Dievini Hopp [not announced whether credit or investment] |
2017-02-06 |
| Coral BioNet–UV-Cap: investment, 201702 acquisition 100% of Scil Proteins GmbH from Bionet Ventures GmbH by UV-Cap GmbH & Co KG |
2017-02-03 |
| Leukocare–Rentschler: investment, 201702 acquisition of 10% stake in Leukocare AG by Rentschler Biotechnologie GmbH as part of strategic alliance |
2017-02-02 |
| Ottobock–Steeper: prosthetic, 201702 acquisition of BeBionic hand product range by Ottobock from Steeper |
2017-02-02 |
| Rentschler–Leukocare: drug formulation technology, 201702– collab strategic alliance using SPS technology for biopharmaceuticals |
2017-02-02 |
| Immunic–Saxony-Anhalt (govt): investment, 201702 investment Series A €4m by new investor IBG bringing total to €21.7m |
2017-02-01 |
| Lonza–SEVERAL: investment, 201701–201702 capital increase CHF865m placing 5m new shares at CHF173/share to selected/qualified investors |
2017-01-31 |
| Regeneron–Indivumed: tissue banking, 201701– collab + supply €na tissue samples w clinical + molecular data for cancer research |
2017-01-31 |
| Medizinsches Labor Bremen–Sonic Healthcare: investment, 201701– acquisition for €63m (cash + debt free) of MLB by Sonic Healthcare Ltd |
2017-01-30 |
| ProteomeTools project–BioNTech: proteomics, 201701 collab existent JPM Peptide Technologies is project partner |
2017-01-30 |
| ProteomeTools project–SAP: proteomics, 201701 collab existent SAP is project partner |
2017-01-30 |
| ProteomeTools project–Thermo Fisher: proteomics, 201701 collab existent Thermo Fisher Scientific is project partner |
2017-01-30 |
![[LSG] Life-Sciences-Germany.com - The Life Sciences Web Portal for German-speaking Europe](/images/basics/lsg-life-sciences-germany-portal-logo-2019.png){kind=logo}
1 2 3 ... 23 24 25 ... 29 30 31 
Date
![Picture [iito] LSE iitoLifeScience Life Sciences Mass Spec 120x120px](/banner/iito-business-intelligence-20111029-120-120-twitter-iitolifescience-germany-europe-mass-spec.jpg)
![Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 120x600px](/banner/iito-20181119-120-600-lsus-life-sciences-usa-com.jpg)
